Cartesian Therapeutics, Inc.
A clinical-stage company developing mRNA-engineered cell therapies for autoimmune diseases.
RNAC | US
Overview
Corporate Details
- ISIN(s):
- US8162121045
- LEI:
- Country:
- United States of America
- Address:
- 7495 NEW HORIZON WAY, 21703 FREDERICK
- Sector:
- Manufacturing
Description
Cartesian Therapeutics, Inc. is a clinical-stage company that pioneers the development of mRNA-engineered cell therapies. The company's primary focus is on creating treatments for autoimmune diseases. Leveraging its novel mRNA technology platform, Cartesian develops therapeutic cells designed to target the drivers of these conditions. This approach aims to expand the reach and potential of cell therapy for patients with various autoimmune disorders. The company's lead asset, Descartes-08, is a central component of its clinical pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cartesian Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cartesian Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cartesian Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
